Hepatitis C and Liver Transplantation

Transplantation of the Liver

Volumn , Issue , 2005, Pages 143-159

  Berenguer, Marina ^a   Lake, John ^b,c,d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Division of Gastroenterology   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33749344561     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0118-2.50015-X     Document Type: Chapter

References (105)

1. United Network for Organ Sharing. Available at http://www.unet.org Accessed May 2002.
2. LB Seeff (2002) Natural history of chronic hepatitis C. Hepatology 36(5 Suppl 1), S35-S46.
3. MG Ghany, DE Kleiner, H Alter, et al. (2003) Progression of fibrosis in chronic hepatitis C. Gastroenterology 124 97-104.
4. G Fattovitch, G Giustina, F Degos, et al. (1997) Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 112 463-472.
5. L Serfarty, H Aumaitre, O Chazouillères, et al. (1998) Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27 1435-1440.
6. KQ Hu and MJ Tong (1999) The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29 1311-1316.
7. T Poynard, J McHutchison, M Manns, et al. (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 1303-1313.
8. TL Wright (2002) Treatment of patients with hepatitis C and cirrhosis. Hepatology 36(5 Suppl 1), S185-S194.
9. GL Davis, JE Albright, SF Cook and DM Rosenberg (2003) Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9 331-338.
10. RH Wiesner, SV McDiarmid and PS Kamath (2001) MELD and PELD: Application of survival models to liver allocation. Liver Transpl 7 567-580.
11. NN Onaca, MF Levy, GJ Netto, et al. (2003) Pretransplant MELD score as a predictor of outcome after liver transplantation for chronic hepatitis C. Am J Transplant 3 626-630.
12. Y Suarez, ACV Franca, JM Llovet, et al. (2000) The current status of liver transplantation for primary hepatic malignancy. Clin Liver Dis 4 591-605.
13. M Garcia-Retortillo, X Forns, A Feliu, et al. (2002) Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35 680-687.
14. O Chazouilleres, M Kim, C Combs, et al. (1994) Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 106 994-999.
15. JE Everhart, Y Wei, H Eng, et al. (1999) Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 29 1220-1226.
16. M Charlton, E Seaberg, R Wiesner, et al. (1998) Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28 823-830.
17. R Sreekumar, A Gonzalez-Koch, Y Maor-Kendler, et al. (2000) Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 32 1125-1130.
18. E Gane, B Portmann, N Naoumov, et al. (1996) Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334 815-820.
19. M Prieto, M Berenguer, M Rayón, et al. (1999) High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 29 250-256.
20. M Berenguer, M Rayón, M Prieto, et al. (2001) Are post-transplantation protocol liver biopsies useful in the long-term? Liver Transpl 7 790-796.
21. M Sebagh, K Rifai, C Feray, et al. (2003) All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 37 1293-1301.
22. M Berenguer, FX Lopez-Labrador and TL Wright (2001) Hepatitis C and liver transplantation. J Hepatol 35 666-678.
23. LM Petrovic, FG Villamil, JM Vierling, et al. (1997) Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation. Liver Transpl Surg 3 398-406.
24. M Guido and SN Thung (1998) Distinguishing rejection from recurrent viral hepatitis on liver biopsy. Viral Hepatitis 4 127-136.
25. M Charlton and E Seaberg (1999) Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 5(Suppl), S107-S114.
26. R Sreekumar, DL Rasmussen, RH Wiesner and MR Charlton (2002) Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 8 814-821.
27. C Feray, L Caccamo, GJM Alexander, et al. (1999) European Collaborative Study on factors influencing the outcome after liver transplantation for hepatitis C. Gastroenterology 117 619-625.
28. G Testa, JS Crippin, GJ Netto, et al. (2000) Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 6 553-561.
29. A Sanchez-Fueyos, J-C Restrepo, L Quintó, et al. (2002) Impact of the recurrence of hepatitis C infection after liver transplantation on the long term viability of the graft. Transplantation 73 56-63.
30. M Berenguer, M Prieto, F San Juan, et al. (2002) Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36 202-210.
31. L Schluger, P Sheiner, S Thung, et al. (1996) Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 23 971-976.
32. AL Doughty, JD Spencer, YE Cossart and GW McCaughan (1998) Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 4 15-21.
33. GW McCaughan and A Zekry (2002) Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 8(Suppl 1), S7-S13.
34. M Berenguer, L Ferrell, J Watson, et al. (2000) HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 32 673-684.
35. M Berenguer, M Prieto, JM Rayon, et al. (2000) Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 32 852-858.
36. M Berenguer, J Crippin, R Gish, et al. (2003) A model to predict severe HCV-related disease following liver transplantation. Hepatology 38 34-41.
37. LM Forman, JD Lewis, JA Berlin, et al. (2002) The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 889-896.
38. AA Prachalias, A Pozniak, C Taylor, et al. (2001) Liver transplantation in adults coinfected with HIV. Transplantation 72 1684-1688.
39. GW Neff, A Bonham, AG Tzakis, et al. (2003) Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 9 239-247.
40. H Rosen, S Chou, C Corless, et al. (1997) Cytomegalovirus viremia. Risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64 721-726.
41. KW Burak, WK Kremers, KP Batts, et al. (2002) Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 8 362-369.
42. PA Sheiner, ME Schwartz, E Mor, et al. (1995) Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 21 30-34.
43. M Berenguer, M Prieto, J Córdoba, et al. (1998) Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 28 756-763.
44. E Gane, N Naoumov, K Qian, et al. (1996) A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 110 167-177.
45. HR Rosen, CR Shackleton, L Higa, et al. (1997) Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 92 1453-1457.
46. JD Eason, S Nair, AJ Cohen, et al. (2003) Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 75 1396-1399.
47. S Brillanti, M Vivarelli, N De Ruvo, et al. (2002) Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 8 884-888.
48. DR Nelson, C Soldevila-Pico, A Reed, et al. (2001) The effect of anti-interleukin-2 receptor therapy on the course of hepatitis C recurrence after liver transplantation. Liver Transpl 7 1064-1070.
49. M Bahra, UP Neumann, M Harren, et al. (2002) Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: Impact on clinical course and histologic damage. Transplant Proc 34 2934-2935.
50. L Fischer, M Sterneck, CG Gahlemann, et al. (2000) Prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transplant Proc 32 2125-2127.
51. A Jain, R Kashyap, AJ Demetris, et al. (2002) A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 8 40-46.
52. CG Fasola, GJ Netto, LW Jennings, et al. (2002) Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 34 1563-1564.
53. Y Calmus, JR Scheele, I Gonzalez-Pinto, et al. (2002) Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 8 123-131.
54. P Neuhaus, PA Clavien, D Kittur, et al. (2002) Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. Liver Transpl 8 132-142.
55. M Berenguer (2002) Outcome of post-transplantation HCV-disease—is it the host, the virus or how we modify the host and/or the virus? Liver Transpl 8 889-891.
56. HR Rosen, JJ Lentz, SL Rose, et al. (1999) Donor polymorphism of tumor necrosis factor gene. Relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation 68 1898-1902.
57. R Manez, R Mateo, J Tabasco, et al. (1994) The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation 59 640-642.
58. SJ Cotler, LK Gaur, DR Gretch, et al. (1998) Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens 52 435-443.
59. V Di Martino, F Saurini, D Samuel, et al. (1997) Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 26 1343-1350.
60. S Zhou, N Terrault, L Ferrell, et al. (1996) Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia. Hepatology 24 1041-1046.
61. HE Vargas, T Laskus, LF Wang, et al. (1998) The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 4 22-27.
62. V Di Martino, C Brenot, D Samuel, et al. (2000) Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on Fas-mediated apoptosis after liver transplantation for hepatitis C. Transplantation 70 1390-1396.
63. M Gigou, AM Roque-Alfonso, B Falissard, et al. (2001) Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol 75(11), 211-292. 297
64. DG Sullivan, JJ Wilson, RL Carithers Jr, et al. (1998) Multigene tracking of hepatitis C virus quasispecies after liver transplantation: Correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 72 10,036-10,043.
65. AL Doughty, DM Painter and GW McCaughan (2000) Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. J Hepatol 32 10-20.
66. MG Pessoa, NH Bzowej, M Berenguer, et al. (1999) Evolution of hepatitis C (HCV) quasispecies in patients with severe cholestatic hepatitis following liver transplantation. Hepatology 30 1513-1520.
67. SJ Pelletier, DP Raymond, TD Crabtree, et al. (2000) Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation. Hepatology 32 375-381.
68. SJ Pelletier, DP Raymond, TD Crabtree, et al. (2000) Hepatitis C-induced hepatic allograft injury is associated with a pre-transplantation elevated viral replication rate. Hepatology 32 418-426.
69. M Wali, RF Harrison, PJ Gow and D Mutimer (2002) Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51 248-252.
70. CJ Imber, SD St Peter, I Lopez, et al. (2002) Current practice regarding the use of fatty livers: A trans-Atlantic survey. Liver Transpl 8 545-549.
71. T Laskus, LF Wang, J Rakela, et al. (1996) Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology 220 171-176.
72. G Testa, RM Goldstein, G Netto, et al. (1998) Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 65 925-929.
73. HE Vargas, T Laskus, LF Wang, et al. (1999) Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 117 149-153.
74. E Velidedeoglu, NM Desai, L Campos, et al. (2002) The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 73 582-587.
75. PW Baron, D Sindram, D Higdon, et al. (2000) Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 6 407-412.
76. HR Rosen, DR Gretch, M Oehlke, et al. (1998) Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 65 1178-1182.
77. M Guido, S Fagiuoli, G Tessari, et al. (2002) Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut 50 697-700.
78. C Feray, M Gigou, D Samuel, et al. (1998) Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 128 810-816.
79. M Berenguer, NA Terrault, M Piatak, et al. (1996) Hepatitis G virus infection in patients with hepatitis C virus infection undergoing liver transplantation. Gastroenterology 111 1569-1575.
80. J Neuberger, KH Schulz, C Day, et al. (2002) Transplantation for alcoholic liver disease. J Hepatol 36 130-137.
81. B Willems, M Ede, P Marotta, et al. (2002) Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study [abstract]. J Hepatol 36(Suppl 1), 96.
82. JS Crippin, P Sheiner, NA Terrault, et al. (2002) A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transpl 8 350-355.
83. GT Everson, T Trouillot, J Trotter, et al. (2000) Treatment of decompensated cirrhotics with a slow-accelerating dose regimen (LADR) of interferon-alfa-2b plus ribavirin: Safety and efficacy [abstract]. Hepatology 32 308A.
84. P Sheiner, P Boros, FM Klion, et al. (1998) The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 28 831-838.
85. N Singh, T Gayowski, C Wannstedt, et al. (1998) Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 65 82-86.
86. V Mazzaferro, A Tagger, M Schiavo, et al. (2001) Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 33 1355-1357.
87. N Terrault, M Khalili, K Bollinger, et al. (2002) Limitations in the use of a prophylactic antiviral strategy in hepatitis C infected patients undergoing liver transplantation [abstract]. Hepatology 36 177A.
88. TL Wright, C Combs, M Kim, et al. (1994) Interferon alpha therapy for hepatitis C virus infection following liver transplantation. Hepatology 20 773-779.
89. C Feray, D Samuel, M Gigou, et al. (1995) An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 22 1084-1089.
90. EJ Gane, SK Lo, SM Riordan, et al. (1998) A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 27 1403-1407.
91. T Bizollon, U Palazzo, C Ducerf, et al. (1997) Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 26 500-504.
92. AB Alberti, LS Belli, A Airoldi, et al. (2001) Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 7 870-876.
93. DV Gopal, JM Rabkin, BS Berk, et al. (2001) Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 7 181-190.
94. J Ahmad, SF Dodson, AJ Demetris, et al. (2001) Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 7 863-869.
95. ME De Vera, GA Smallwood, K Rosado, et al. (2001) Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 71 678-686.
96. M Narayanan, JJ Poterucha, OM El-Amin, et al. (2002) Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transpl 8 623-629.
97. B Lavezzo, A Franchello, A Smedile, et al. (2002) Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J Hepatol 37 247-252.
98. D Samuel, T Bizollon, C Feray, et al. (2003) Interferon-alfa 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 124 642-650.
99. S Saab, D Ly, SB Han, et al. (2002) Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 8 449-457.
100. PA Sheiner, LK Schluger, S Emre, et al. (1997) Retransplantation for recurrent hepatitis C. Liver Transpl Surg 3 130-136.
101. H Rosen, P O'Reilly, C Shackleton, et al. (1997) Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 62 1773-1776.
102. HR Rosen, JP Madden and P Martin (1999) A model to predict survival following liver retransplantation. Hepatology 29 365-370.
103. RW Busuttil, A Shaked, JM Millis, et al. (1994) One thousand liver transplants. The lessons learned. Ann Surg 219 490-499.
104. M Berenguer, M Prieto, A Palau, et al. (2002) Severe recurrent hepatitis C following liver retransplantation for HCV-related graft failure. Liver Transpl 9 228-235.
105. SW Biggins, A Beldecos, JM Rabkin and HR Rosen (2002) Retransplantation for hepatic allograft failure: Prognostic modeling and ethical considerations. Liver Transpl 8 313-322.